sermorelin


Also found in: Wikipedia.

sermorelin

 [ser″mo-rel´in]
a synthetic peptide corresponding to a portion of growth hormone–releasing hormone; used as the acetate salt in treatment of growth hormone deficiency in prepubertal children, administered subcutaneously.

sermorelin

/ser·mo·rel·in/ (ser″mo-rel´in) a synthetic peptide corresponding to a portion of growth hormone; used as the acetate salt in the treatment of growth hormone deficiency.

sermorelin

[ser′mo-rel′in]
a synthetic peptide corresponding to a portion of growth hormone-releasing hormone, used as the acetate salt in treatment of growth hormone deficiency in prepubertal children. It is administered subcutaneously.

sermorelin

A growth hormone releasing factor used as a drug to treat growth failure. A brand name is Geref.
References in periodicals archive ?
US Peptides carries a variety of products such as: Melanotan II, CJC-1295, GHRP-6, Sermorelin, IGF1-LR3, GHRP-2, Fragment 176-191, CJC-1295 DAC, Mechano Growth Factor - PEG, Mechano Growth Factor, Hexarelin, Ipamorelin, Melanotan I, Bacteriostatic 0.
Florida Peptides carries a variety of products such as: CJC-1295, GHRP-6, Sermorelin, GHRP-2, CJC-1295 DAC, Bacteriostatic 0.
Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH2) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues.
The free base of sermorelin has the empirical formula C149H246N44O42S and a molecular weight of 3,358 daltons.
5 mg sermorelin (as the acetate) and 5 mg mannitol.
In subcutaneous administration of 2 mg sermorelin to 12 normal volunteers, peak concentrations of sermorelin were reached in 5-20 minutes.
Sermorelin is rapidly cleared from the circulation, with clearance values in adults ranging between 2.
The structural formula for sermorelin acetate is presented
Sermorelin increases plasma growth hormone (GH) concentrations by
Geref(R) Diagnostic is contraindicated in patients hypersensitive to sermorelin acetate or any of the excipients.
subcutaneous administration of large doses of sermorelin (see Adverse
frequency, have been reported following sermorelin administration: